{"product_id":"biolegend-106306","title":"Biolegend, 106306, PE anti-mouse CD152 Antibody, 200μg","description":"\u003cp\u003eCD152, also known as CTLA-4 or Ly-56, is a 33 kD member of the immunoglobulin superfamily. It is expressed on activated T and B lymphocytes. CD152 is similar to CD28 in amino acid sequence, structure, and genomic organization and these two receptors share common B7 family counter-receptors (B7-1, B7-2). Whereas CD28 delivers a costimulatory signal in T cell activation, CTLA-4 negatively regulates cell-mediated immune responses. CD152 is thought to play a role in the induction and maintenance of immunological tolerance as well as the development of protective immunity and thymocyte regulation.\u003cbr\u003e\n200μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Armenian Hamster\u003cbr\u003e\nImmunogen: Mouse CTLA-4-mouse IgG2a fusion protein\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.\u003cbr\u003e\nConcentration: 0.2 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nExcitation Laser: Blue Laser (488 nm)Green Laser (532 nm)\/Yellow-Green Laser (561 nm)\u003cbr\u003e\nApplication Notes: The UC10-4B9 antibody can enhance T cell co-stimulation by blocking CTLA-4 interactions with the B7 co-receptors, favoring CD28 interactions. Additional reported applications (for the relevant formats) include: immunoprecipitation1, in vitro stimulation, in vitro and in vivo blocking1-4 of ligand binding, and as ELISA capture antibody5. To reduce non-specific binding to cells bearing Fc-receptors, pre-incubation of cells with anti-mouse CD16\/CD32, clone 93 (Cat. No. 101301\/101302), is recommended prior to immunofluorescent staining. For most successful immunofluorescent staining results, it may be important to maximize signal over background by using a relatively bright fluorochrome-antibody conjugate (Cat. No. 106306) or by using a high sensitivity, three-layer staining technique (e.g., including a biotinylated anti-Armenian hamster IgG (Cat. No. 405501) second step, followed by SAv-PE (Cat. No. 405204)). The Ultra LEAF™ purified antibody (Endotoxin \u0026lt; 0.01 EU\/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 106327).\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Walunas TL, et al. 1994. Immunity 1:405. (Block, IP) Cilio CM, et al. 1998. J. Exp. Med. 188:1239. (Block) Issazadeh S, et al. 1999. J. Immunol. 162:761. (Block) McCoy K, et al. 1997. J. Exp. Med. 186:183. (Block) Hsu HC, et al. 2007. J. Immunol. 178:5357. (ELISA Capture) Sugita S, et al. 2010. Invest. Ophthalmol. Vis. Sci. 51:5783. PubMed\u003cbr\u003e\nProduct Citations: Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed Schwarz A, et al. 2023. Front Immunol. 14:1038689. PubMed Xiao X, et al. 2023. Nat Commun. 14:2859. PubMed Saxena V, et al. 2022. Cell Rep. 39:110727. PubMed Broadfield LA, et al. 2022. Mol Metab. 61:101498. PubMed Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed Ivasko SM, et al. 2023. Front Immunol. 13:1023206. PubMed Zenke S, et al. 2022. Nat Commun. 13:6459. PubMed Wang L, et al. 2019. Cell Rep. 29:1848. PubMed Denk D, et al. 2022. Immunity. 55:2059. PubMed Qi Z, et al. 2022. Nat Commun. 13:182. PubMed Shi B, et al. 2018. J Immunol. 200:586. PubMed Turner JA, et al. 2020. Immunity. 53:1202. PubMed Sugita S, et al. 2010. Invest Ophthalmol Vis Sci. 51:5783. PubMed Wu M, et al. 2021. Nat Commun. 12:3500. PubMed Alikhan M, et al. 2016. J Am Soc Nephrol. 27: 706 - 714. PubMed DeLong JH, et al. 2019. Immunohorizons. 3:13. PubMed Thauland T, et al. 2014. J Immunol. 193:5894. PubMed Singh K, et al. 2015. Sci Rep. 14:7767. PubMed Wei SC, et al. 2020. Cancer Discov. . PubMed An J, et al. 2022. iScience. 25:103570. PubMed Xu L et al. 2017. Immunity. 47(3):538-551 . PubMed Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed Ren J, et al. 2019. PLoS Biol. 17:e3000270. PubMed Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed Andersen L, et al. 2020. Cell Reports. 29(13):4447-4459.e6.. PubMed De Ponte Conti B, et al. 2021. Elife. 10:. PubMed Benci JL et al. 2019. Cell. 178(4):933-948 . PubMed Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed Montalban-Arques A, et al. 2021. Cell Host Microbe. :. PubMed Elliot TAE, et al. 2021. Immunity. 54:2481. PubMed Zhang GL, et al. 2020. Matrix Biol. 93:25. PubMed Hu J, et al. 2022. J Immunother Cancer. 10:. PubMed Halim TYF et al. 2018. Immunity. 48(6):1195-1207 . PubMed Li J, et al. 2021. Cell Rep. 37:110124. PubMed Rinaldi S, et al. 2021. PLoS Pathog. 17:e1009533. PubMed Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed\u003cbr\u003e\nRRID: AB_313254 (BioLegend Cat. No. 106305) AB_313255 (BioLegend Cat. No. 106306)\u003cbr\u003e\nStructure: Ig superfamily, 33 kD\u003cbr\u003e\nDistribution: Activated T cells and B cells\u003cbr\u003e\nFunction: Negative regulator of T cell activation\u003cbr\u003e\nLigand\/Receptor: CD80 (B7-1), CD86 (B7-2)\u003cbr\u003e\nCell Type: B cells, T cells, Tregs\u003cbr\u003e\nBiology Area: Immunology\u003cbr\u003e\nMolecular Family: CD Molecules, Immune Checkpoint Receptors\u003cbr\u003e\nAntigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Allison JP, et al. 1995. Science 270:932. 3. Waterhouse P, et al. 1995. Science 270:985. 4. Linsley PS, et al. 1991. J. Exp. Med. 174:561.\u003cbr\u003e\nGene ID: 12477\u003cbr\u003e\nUniProt: View information about CD152 on UniProt.org\u003cbr\u003e\nClone: UC10-4B9\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4), Ly-56\u003cbr\u003e\nIsotype: Armenian Hamster IgG\u003cbr\u003e\nQ: What type of PE do you use in your conjugates?\u003cbr\u003e\nA: We use R-PE in our conjugates.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46864066543785,"sku":"106306","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/biolegend-106306","provider":"Iright","version":"1.0","type":"link"}